Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5

Starting soon · Phase 2

Conditions studied: Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5

In brief

Patients with severe, rapidly progressive diffuse interstitial lung disease (RP ILD) with anti-MDA5 have an appalling prognosis and the lack of effective medical treatment leads to lung transplantation being proposed as salvage treatment. Currently, transplant-free survival at 90 days (D90) is approximately 25%, dropping to less to 10% among those requiring mechanical ventilation. Peripheral lymphopenia and elevated anti-MDA5 antibody levels are associated with greater disease severity, highlighting the involvement of mature T and B lymphocytes in disease pathogenesis. Teclistamab, a bispecific antibody targeting the B-cell maturation antigen (BCMA) on plasma cells and engaging T cells - approved for the treatment of refractory multiple myeloma - has recently shown rapid and promising effects in patients with autoimmune conditions, including one MDA5-positive patient, while maintaining a favourable safety profile. We hypothesize that this bispecific antibody could represent a promising and safe therapeutic option for patients with severe MDA5-associated RP-ILD.

Key facts

Study ID

NCT07631208

Run by

Assistance Publique - Hôpitaux de Paris

People needed

24

Starts

2026-10-30

Expected to finish

2027-01-01

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient ≥ 18 years old
• MDA5 antibody positivity
• ILD confirmed by chest HRCT
• Within less than 3 months after disease onset
• Refractory after more than 7 days to high dose steroids and two immunosuppressants drugs as first-line treatment.
• Confirmation of refractoriness by the national emergency multidisciplinary discussion (MDD),
• Worsening of respiratory symptoms with respiratory distress defined by increase in oxygen supply to reach SpO2>95% or requirement of mechanical ventilation
• Written informed consent obtained from the patient or the trusted support person designated in advance by the patient
• Patients covered by the French social security system
• Effective contraception for woman of childbearing age during treatment and for five months after the last dose of teclistamab.
• Effective contraception for men, having a partner of childbearing age, during treatment and for three months after the last dose of teclistamab.

You may not qualify if…

• Patient with known hypersensitivity to teclistamab, substance active or excipients, including sodium or polysorbate
• Patient or the trusted person designed by the patient not able to give their consent
• Known diagnosis of a serious comorbidity: active cancer, malignant blood disease, ongoing infection, stroke or seizure within 6 months
• Patient who received a live vaccine within 4 weeks prior to study inclusion.
• Patient under judicial protection, deprivation of liberty
• Patient participating in another clinical trial with an investigational medicinal product
• Pregnant or breastfeeding woman
• Patient on AME (state medical aid)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.